Patent intelligence · US
US 11925663
Methods of managing tumor flare in adoptive immunotherapy
Methods of managing tumor flare in adoptive immunotherapy
Patent details — US 11925663
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 12, 2024
- Expiration
- Mar 7, 2044
- Applicant
- Atara Biotherapeutics, Inc.
- Claims
- 25
- CPC classes
- A61K, A61K2039/545, A61K2039/585, A61K2239/31
Quick answer
US 11925663 (Methods of managing tumor flare in adoptive immunotherapy) is held by Atara Biotherapeutics, Inc.. Status: granted. Granted Mar 12, 2024. Expires Mar 7, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Atara Biotherapeutics, Inc.
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K2039/545, A61K2039/585, A61K2239/31, A61K2239/38, A61K2239/48
More from Atara Biotherapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12383572
Administration of an anti-activin-a compound to a subject
granted -
US 11541070
Administration of an anti-activin-A compound to a subject
granted -
US 9968586
Mast cell stabilizers treatment for systemic disorders
granted -
US 9962363
Mast cell stabilizers treatment for systemic disorders
granted -
US 9707206
Mast cell stabilizers treatment for systemic disorders
granted -
US 9265749
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
granted -
US 8501678
Variant activin receptor polypeptides and uses thereof
granted
Frequently asked questions
What is US patent 11925663?
US 11925663 (Methods of managing tumor flare in adoptive immunotherapy) is held by Atara Biotherapeutics, Inc.. Status: granted. Granted Mar 12, 2024. Expires Mar 7, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11925663?
Atara Biotherapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 11925663 expire?
Our index shows an expiration date of Mar 7, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.